Nectin Therapeutics
Biotechnology, 184 Liberty Cor Rd, Warren, New Jersey, 07059, United States, 1-10 Employees
Phone Number: +19*********
Who is NECTIN THERAPEUTICS
Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecede...
Read More
-
Headquarters: 184 Liberty Cor Rd, Warren, New Jersey, 07059, United States
-
Date Founded: 2017
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Fabian Tenenbaum
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541711 |
Show More
Does something look wrong? Fix it. | View contact records from NECTIN THERAPEUTICS
Nectin Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Nectin Therapeutics
Answer: Nectin Therapeutics's headquarters are located at 184 Liberty Cor Rd, Warren, New Jersey, 07059, United States
Answer: Nectin Therapeutics's phone number is +19*********
Answer: Nectin Therapeutics's official website is https://nectintx.com
Answer: Nectin Therapeutics's revenue is $5 Million to $10 Million
Answer: Nectin Therapeutics's SIC: 2834
Answer: Nectin Therapeutics's NAICS: 541711
Answer: Nectin Therapeutics has 1-10 employees
Answer: Nectin Therapeutics is in Biotechnology
Answer: Nectin Therapeutics contact info: Phone number: +19********* Website: https://nectintx.com
Answer: Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month